Exosomes released from cancers contain oncoproteins and miRNAs wh

Exosomes released from cancers contain oncoproteins and miRNAs which may promote cancer progression. A novel technology which consists of immobilized affinity agents in the outer-capillary space of hollow-fibre plasma separator cartridges that integrate into standard dialysis

machines has been BYL719 devised. This technology is currently being evaluated for its efficacy for capturing exosomes secreted by cancer cell lines and present in biological fluids from cancer patients[106] and could potentially be applied to other situations such as atherosclerosis in which circulating microvesicles might have pathogenic roles. While there is an increasing appreciation of the existence and potential functions of exosomes and other vesicles, some very fundamental questions remain. Are there distinct cell-specific types or families of exosomes with well-defined sizes, cargos and differing functions? How is exosomal cargo modified? What are the physiological and pathological stimuli to their production, release and uptake? What are their physiological signalling roles in the circulation and urine? What receptors or other mechanisms define their target cells? What is the effect of renal FDA-approved Drug Library chemical structure function and disease

on the levels and nature of circulating and urinary exosomes? Addressing these questions should provide new insights in the intercellular communication mechanism and enable a more sophisticated translation of the use of exosomes as novel biomarkers and therapeutic intervention strategies. “
“Aim:  Haemodiafiltration (HDF) is the most efficient blood purification method and can remove a wide spectrum of solutes of different molecular weights (MW). The purpose of this study was to investigate whether the removed amounts of solutes, especially the larger molecules, could be

increased by changing the HDF filtration Proteasome inhibitor procedure. Methods:  A new first-half intensive HDF treatment (F-HDF) was designed, whereby convective clearance is intensively forced during the first half of a HDF session. We compared the removed amounts of solutes in the same group of nine patients treated by F-HDF, constant rate-replacing HDF (C-HDF) and a high-flux haemodialysis (HD). Results:  F-HDF can remove significantly larger amounts of α1-microglobulin (MG), molecular weight (MW) 33 000, compared with HD and C-HDF (30.1 ± 15.1 vs 12.4 ± 0.3, 15.0 ± 3.1 mg, P < 0.01). Regarding the removal amounts and clear space of β2MG, MW 11 800, there were no significant differences between the three treatment modalities. Regarding amounts of creatinine, urea nitrogen and phosphorus, there were no significant differences between the three treatment modalities.

Comments are closed.